VANFLYTA treatment is associated with a range of common adverse reactions, including significant laboratory abnormalities and clinically notable events such as febrile neutropenia and infections.

Common and Serious Adverse Reactions with VANFLYTA

The most common (>20%20%) adverse reactions, including laboratory abnormalities, observed with VANFLYTA include decreased lymphocytes, potassium, albumin, phosphorus, and magnesium; increased alkaline phosphatase; febrile neutropenia; diarrhea; mucositis; nausea; decreased calcium; abdominal pain; sepsis; neutropenia; headache; increased creatine phosphokinase; vomiting; and upper respiratory tract infections. Serious adverse reactions in ≥5%≥5% of patients included febrile neutropenia (11%). Fatal adverse reactions occurred in 10% of patients receiving VANFLYTA, with sepsis being the most frequent cause (5%). Permanent discontinuation due to adverse reactions occurred in 20% of patients.